Eli Lilly and Company (NYSE:LLY) Trading Up 0.6% – What’s Next?

Eli Lilly and Company (NYSE:LLY) was up 0.6% on Friday . The company traded as high as $900.96 and last traded at $896.88. Approximately 599,380 shares were traded during trading, a decline of 80% from the average daily volume of 2,951,049 shares. The stock had previously closed at $891.32.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on LLY shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Citigroup assumed coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective on the stock. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,002.24.

Eli Lilly and Company Stock Up 0.5 %

The firm’s fifty day moving average price is $920.32 and its two-hundred day moving average price is $860.96. The stock has a market cap of $851.67 billion, a price-to-earnings ratio of 132.09, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Sell-side analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently made changes to their positions in LLY. Jessup Wealth Management Inc acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $303,000. Buckley Wealth Management LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth about $384,000. Courage Miller Partners LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth about $254,000. Fifth Third Wealth Advisors LLC grew its position in Eli Lilly and Company by 11.0% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 7,536 shares of the company’s stock worth $5,863,000 after purchasing an additional 746 shares in the last quarter. Finally, Indiana Trust & Investment Management CO grew its position in Eli Lilly and Company by 5.7% in the 1st quarter. Indiana Trust & Investment Management CO now owns 16,380 shares of the company’s stock worth $12,743,000 after purchasing an additional 880 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.